I-Mab Biopharma
I-Mab Biopharma, a leading biopharmaceutical company headquartered in China, focuses on the discovery and development of innovative therapies for cancer and autoimmune diseases. Founded in 2015, I-Mab has rapidly established itself in the global biopharma landscape, with significant operational presence in both China and the United States. The company is renowned for its robust pipeline of monoclonal antibodies and proprietary drug candidates, which are designed to address unmet medical needs. Notable achievements include strategic partnerships and collaborations that enhance its research capabilities and market reach. With a commitment to advancing healthcare through cutting-edge science, I-Mab Biopharma continues to position itself as a key player in the biopharmaceutical industry, dedicated to improving patient outcomes worldwide.
DitchCarbon Score
How does I-Mab Biopharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
I-Mab Biopharma's score of 20 is lower than 83% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
I-Mab Biopharma's reported carbon emissions
I-Mab Biopharma, headquartered in China (CN), currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that I-Mab Biopharma may not have established formal commitments to reduce carbon emissions or engage in climate initiatives at this time. As the biopharmaceutical industry increasingly prioritises sustainability, I-Mab's future climate commitments will be crucial for aligning with industry standards and expectations.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
I-Mab Biopharma is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
